Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy
Выживаемость при первичной легочной гипертензии
2002-09-16
SCID: 54.1/2wztszvd
Discuss with AI
intravenous epoprostenollong-term survivalprimary pulmonary hypertensionpulmonary hemodynamicsvasodilator response
Figures from the paper
Abstract (AI)
BACKGROUND: Primary pulmonary hypertension (PPH) is a severe and progressive disease. Without treatment, the median survival is 2.8 years, with survival rates of 68%, 48%, and 34% at 1, 3, and 5 years, respectively. Intravenous epoprostenol was the first Food and Drug Administration-approved therapy for PPH. The long-term impact that epoprostenol has made on PPH remains to be defined. METHODS AND RESULTS: One hundred sixty-two consecutive patients diagnosed with PPH and treated with epoprostenol were followed for a mean of 36.3 months (median, 31 months). Data including functional class, exercise tolerance, and hemodynamics were recorded in a customized database. Vital status was verified in each patient. Observed survival with epoprostenol therapy at 1, 2, and 3 years was 87.8%, 76.3%, and 62.8% and was significantly greater than the expected survival of 58.9%, 46.3%, and 35.4% based on historical data. Baseline predictors of survival included exercise tolerance, functional class, right atrial pressure, and vasodilator response to adenosine. Predictors of survival after the first year of therapy included functional class and improvement in exercise tolerance, cardiac index, and mean pulmonary artery pressure. CONCLUSIONS: Intravenous epoprostenol improves long-term survival in PPH.
Key Findings
1
After the first year, survival was predicted by functional class and improvements in exercise tolerance, cardiac index, and mean pulmonary artery pressure.
2
Among 162 epoprostenol-treated patients, observed survival was 87.8% at 1 year, 76.3% at 2 years, and 62.8% at 3 years.
3
Baseline survival predictors included exercise tolerance, functional class, right atrial pressure, and vasodilator response to adenosine.
4
Historical expected survival was substantially lower: 58.9% at 1 year, 46.3% at 2 years, and 35.4% at 3 years.
5
Intravenous epoprostenol significantly improved survival in primary pulmonary hypertension compared with historical untreated outcomes.
Research Object
Patients with primary pulmonary hypertension treated with intravenous epoprostenol
Research Subject
Long-term survival and its clinical, functional, and hemodynamic predictors
Publication Details
Publication Date
2002-09-16
Journal
Publisher
ISSN
Cited by
1219
Access Type
Author Information
Download PDF
Subscribe to digest
Cited by5
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension2015
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension2022
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension2015
Prostacyclin for pulmonary arterial hypertension2019
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension2022